Adma Biologics Inc (ADMA) saw an uptrend of 0.07% in the recent trading with $14.55 being its most recent. The current price level -43.32% lower than the highest price of $25.67 marked by the stock while trading over the past 52-weeks, whereas it is 7.78% higher than the lowest price of $13.50 the company dropped to over past 52-weeks. The latest news story on ADMA appeared in (Zacks) under the title “Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?” on.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
Adma Biologics Inc Earnings – What Happened With ADMA
Coming around sales and income figures on ADMA Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Adma Biologics Inc (ADMA) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 15.38% for net revenue.
ADMA – Adma Biologics Inc Stock Earnings Estimates
The perspective of Adma Biologics Inc (NASDAQ:ADMA)’s current quarter earnings identifies that analysts are in consensus over the estimate of 0.13 for stock’s EPS in the current quarter. Adma Biologics Inc (ADMA) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 15.38% for net revenue. Company’s EPS for the last quarter was 0.15.
Adma Biologics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 239.38 million. ADMA does have institutional investors; and they hold 88.66% of the stock.
As on 2024-06-30, BLACKROCK INC. was the top most holder in Adma Biologics Inc (NASDAQ:ADMA) with an ownership of 18.64 million shares of the company or 8.0221 of the stake worth $208.45 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 6.2459 of the outstanding shares. Its stake is worth $162.3 million for having 14.52 million shares in hand.
INVESCO LTD. also came holding a key position in the company during the recent quarter and it now holds 5.6668 of the outstanding shares. With this there are now 500.0 institutions which have possession in ADMA’s shares.
Key Metrics for ADMA
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Adma Biologics Inc has a debt to equity ratio of 0.21.
